Amy Kiskaddon, PharmD, MBA, is assistant professor at the Department of Pediatrics, Divisions of Pediatric Cardiology and Hematology, Johns Hopkins University School of Medicine, and a Clinical Pharmacy Specialist in the Heart Institute at Johns Hopkins All Children’s Hospital. She also serves as Co-director of the Center for Pediatric Early-Phase Trials at Johns Hopkins All Children’s Institute for Clinical and Translational Research.
After receiving her doctorate of pharmacy from the University of Florida College of Pharmacy in Gainesville, Dr. Kiskaddon completed a general pharmacy residency at the University of Florida Shands Hospital and a pediatric pharmacy residency at Texas Children’s Hospital, Houston. She joined Johns Hopkins in 2017 as a pediatric clinical pharmacy specialist in the Heart Institute at Johns Hopkins All Children’s Hospital.
Dr. Kiskaddon’s scientific interest is in hemostasis, thrombosis, anticoagulation, and clinical pharmacology in children with cardiac disease (congenital and acquired heart disease). She received the Eberhard E. Mammen Award in Thrombosis and Hemostasis in 2023. Dr. Kiskaddon is Chair of the Cardiac Disease Thrombosis and Hemostasis Working Party of the Pediatric and Neonatal Thrombosis and Hemostasis Subcommittee (Pediatric Subcommittee) of the International Society of Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC), is a member of the Antithrombotic Trial Working Party of the Pediatric Subcommittee of the ISTH SSC, and is a member of the Editorial Board of the American Heart Association journal Arteriosclerosis, Thrombosis & Vascular Biology (ATVB). She has contributed to consensus statements on anticoagulation in mechanical circulatory support by the International Society for Heart and Lung Transplantation (ISHLT) and speaks nationally and internationally on anticoagulation and clinical pharmacology in children, anticoagulation in pediatric cardiac disease, and anticoagulation in pediatric mechanical circulatory support. She is also a member of the Steering Committee of a phase 4 multicenter prospective study evaluating the use and outcomes of the direct oral anticoagulant dabigatran for the treatment of venous thromboembolism in children in real-world experience.